Hiroatsu Sakamoto Sakamoto

Dr. Hiroatsu Sakamoto Sakamoto


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in Medicina
Verified
Journal Article
Open access
PDF file
AKAtsuhiro Kitaura
Atsuhiro Kitaura
HSHiroatsu Sakamoto Sakamoto
Hiroatsu Sakamoto Sakamoto
SHShinichi Hamasaki
Shinichi Hamasaki
STShota Tsukimoto
Shota Tsukimoto
YNYasufumi Nakajima
Yasufumi Nakajima
Background and Objectives: Remimazolam is a new ultrashort-acting benzodiazepine anesthetic. Remimazolam appears to be useful in patients with severe valvular disease because of its minimal cardiovascular impact. In this retrospective case series study, we assessed the efficacy and safety of remimazolam for maintaining hemodynamic stability during anesthetic induction and maintenance. Cases: MitraClip was performed on 18 cases with severe mitral regurgitation with low left ventricular function who presented with heart failure, and remimazolam was administered for general anesthesia with induction (12 mg/kg/h) and maintenance (1 mg/kg/h). The impact of remimazolam on the hemodynamics at anesthetic induction and during anesthetic maintenance was investigated retrospectively using electronic medical records. Blood pressure decreased significantly during anesthetic induction with remimazolam (78.5 [72, 81.25] and 66.1 [62.2, 74.2], median [IQR], p = 0.0001), but only mildly, by about 10 mmHg. There was no significant change in the cardiac index (2.0 [1.8, 2.4] vs. 1.9 [1.8, 2.3], p = 0.57642) or pulse rate (73.5 ± 8.85 vs. 74.7 ± 11.7, mean ± SD, p = 0.0876) during anesthetic induction with remimazolam. All patients underwent MitraClip without major hemodynamic concerns, with no or small increases in inotropes. Conclusions: Remimazolam may be used safely in patients with severe mitral regurgitation and low left ventricular function presenting with heart failure.

Verified
Journal Article
Open access
PDF file
TMTakashi Mino
Takashi Mino
AKAtsuhiro Kitaura
Atsuhiro Kitaura
HSHiroatsu Sakamoto Sakamoto
Hiroatsu Sakamoto Sakamoto
YYYukari Yoshino
Yukari Yoshino
STShota Tsukimoto
Shota Tsukimoto
YNYasufumi Nakajima
Yasufumi Nakajima
Background/Objectives: Remimazolam, a short-acting benzodiazepine, promotes quick and consistent recovery from anesthesia. However, flumazenil’s rapid antagonistic effects on benzodiazepines during the emergence from anesthesia are thought to increase the risk of postoperative nausea and vomiting (PONV). This study aimed to compare the rate of PONV in monitored anesthesia care (MAC) with remimazolam versus conventional MAC with dexmedetomidine. Methods: This single-center retrospective study included all cases with transcatheter aortic valve replacements (TAVR) performed using MAC at our institution between January 2019 and April 2023. The patients were divided into remimazolam and dexmedetomidine–propofol groups based on the anesthetic method used. We used propensity score matching at a 1:1 ratio to account for the patient backgrounds. The primary outcome measure was the rate of PONV within 48 h. Secondary outcome measures included the severity of PONV and the number of antiemetics administered. Results: This study included 177 subjects. Following propensity score matching, 61 patients were allocated to each group. The incidence of PONV within 48 h after surgery was 4.92% in the remimazolam group and 3.28% in the dexmedetomidine–propofol group, with no significant difference between the two groups (p = 0.817). There was no significant difference between the two groups in terms of the secondary outcomes, including the severity of PONV (p = 0.190) and the use of antiemetics (p = 0.690). Conclusions: In TAVR with MAC and remimazolam, the incidence of PONV within 48 h was comparable to that of dexmedetomidine.

13 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAtsuhiro Kitaura
Atsuhiro Kitaura
TMTakashi Mino
Takashi Mino
YYYukari Yoshino
Yukari Yoshino
HSHiroatsu Sakamoto Sakamoto
Hiroatsu Sakamoto Sakamoto
MMMAYUKA MATSUSHIMA
MAYUKA MATSUSHIMA
YNYasufumi Nakajima
Yasufumi Nakajima
Background/Objectives: Monitored anesthesia care (MAC) is increasingly used for transcatheter aortic valve replacement (TAVR), where rapid recovery of consciousness may facilitate early postoperative neurological assessment. Remimazolam provides sedation that can be pharmacologically reversed with flumazenil. We compared emergence from sedation between a remimazolam–flumazenil-based MAC strategy and a conventional dexmedetomidine-based strategy in patients undergoing transfemoral TAVR. Methods: In this single-center randomized controlled trial, 84 patients undergoing transfemoral TAVR were randomized 1:1 to remimazolam–remifentanil (R group) or dexmedetomidine–propofol–remifentanil (D group) MAC. Flumazenil was administered at the initiation of the postoperative awakening attempt in the R group. The primary outcome was arousal time, assessed using two prespecified measures: time from discontinuation of all anesthetic infusions to arousal and time from initiation of the postoperative awakening attempt to arousal. Arousal was defined as a Modified Observer’s Assessment of Alertness/Sedation score of 5. Results: Eighty-three patients were included in the analysis (R group, n = 42; D group, n = 41). The time from discontinuation of all anesthetic infusions to arousal was shorter in the R group than in the D group (19.05 [15.77–23.59] vs. 24.09 [19.25–34.78] min; p = 0.0045). The time from initiation of the awakening attempt to arousal was also shorter (0.60 [0.33–1.00] vs. 1.00 [0–4.72] min; p = 0.0117). No patient in the R group required rescue propofol. No significant between-group differences were observed in major procedural or postoperative outcomes. Conclusions: A remimazolam-based MAC strategy with flumazenil reversal provided faster and more reliable emergence from sedation than a conventional dexmedetomidine-based strategy during transfemoral TAVR. These findings suggest that a reversible sedation strategy may facilitate rapid recovery of consciousness when early postoperative assessment is desired, although its impact on neurological or other clinical outcomes remains to be established.